Putnam FL Investment Management Co. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 1.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 169,150 shares of the biopharmaceutical company’s stock after selling 1,845 shares during the period. Putnam FL Investment Management Co.’s holdings in Pfizer were worth $7,328,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Fisher Asset Management LLC boosted its stake in shares of Pfizer by 3.3% during the fourth quarter. Fisher Asset Management LLC now owns 41,830,709 shares of the biopharmaceutical company’s stock valued at $1,825,910,000 after purchasing an additional 1,352,978 shares during the period. California Public Employees Retirement System lifted its stake in Pfizer by 14.0% in the fourth quarter. California Public Employees Retirement System now owns 20,333,138 shares of the biopharmaceutical company’s stock worth $887,541,000 after acquiring an additional 2,504,336 shares during the period. Sanders Capital LLC lifted its stake in Pfizer by 3.3% in the second quarter. Sanders Capital LLC now owns 18,749,080 shares of the biopharmaceutical company’s stock worth $910,953,000 after acquiring an additional 606,700 shares during the period. APG Asset Management N.V. raised its holdings in Pfizer by 1.4% in the fourth quarter. APG Asset Management N.V. now owns 16,360,380 shares of the biopharmaceutical company’s stock worth $624,704,000 after purchasing an additional 228,300 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Pfizer by 1.2% in the fourth quarter. Rhumbline Advisers now owns 9,449,884 shares of the biopharmaceutical company’s stock worth $412,487,000 after purchasing an additional 113,506 shares in the last quarter. Institutional investors own 71.81% of the company’s stock.
Pfizer stock traded down $0.52 during mid-day trading on Friday, hitting $36.35. The company had a trading volume of 21,609,556 shares, compared to its average volume of 31,392,730. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27. Pfizer Inc. has a 12-month low of $35.86 and a 12-month high of $46.47. The firm’s fifty day moving average is $42.02. The stock has a market cap of $203.38 billion, a P/E ratio of 12.12, a price-to-earnings-growth ratio of 2.92 and a beta of 0.63.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.96%. Pfizer’s dividend payout ratio (DPR) is 48.00%.
In other news, EVP Frank A. Damelio sold 153,184 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total value of $6,753,882.56. Following the transaction, the executive vice president now owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Pfizer Inc purchased 50,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
PFE has been the subject of a number of recent research reports. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Barclays reiterated a “hold” rating and issued a $41.00 target price on shares of Pfizer in a report on Thursday, May 9th. Morgan Stanley downgraded shares of Pfizer from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $48.00 to $40.00 in a report on Tuesday, July 30th. JPMorgan Chase & Co. set a $46.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, July 29th. Finally, UBS Group reiterated a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a report on Monday, August 5th. Fifteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $46.24.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Dollar Cost Averaging
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.